Novo Holdings Acquires Catalent for $16.5 Billion
Novo Holdings A/S announced that it will acquire Catalent, Inc. in an all-cash transaction that values Catalent at $16.5 billion on an enterprise value basis. The purchase price represents a premium of 16.5% to the closing price of Catalent’s common stock as of February 2, 2024, the last trading day prior to the announcement, and a 47.5% premium to the 60-day volume-weighted average price as of February 2, 2024. Catalent is a contract development and manufacturing organization (CDMO) partner for personalized medicines, blockbuster drugs and consumer health brand extensions. The company was formed in April 2007 when affiliates of the Blackstone Group acquired the core of the... Read More »
Biotechnology Gets the Usual January Boost
The Biotechnology sector roared to life in 2017, posting a record 209 transactions. That’s 20% higher than the 174 deals announced in 2016. The previous record for the sector was set in 2009, with 193 transactions announced in the space. Spending for those 209 deals in 2017 didn’t set new records, but did post an impressive $54.5 billion in disclosed prices. That’s 283% higher than the $18.6 billion recorded in all of 2016, but not close to the secctor’s annual spending record of $93.9 billion, set in 2008. Every January, the Biotechnology Showcase is held in San Francisco, concurrent with the J.P. Morgan Healthcare conference. And every January, this sector sees... Read More »MCOs Make Deals to Combat High Drug Costs
The rising cost of prescription drugs was part of many candidates’ campaign platforms in the 2016 national elections. The topic has not gone away, and is certainly a factor in the dearth of Big Pharma deals in 2017. Through June 15, M&A in the Pharma sector is down 43%, to 44 transactions, compared with the same period in 2016, which had 77 transactions. Spending is also down in for the first six months of 2017. Through June 15, acquirers announced $19.2 billion in committed financing, down 66% from the same period in 2016, when approximately $56.5 billion was spent. There are deals being done, regarding this issue, but most are not M&A. In fact, several managed care... Read More »Schedule a demo
Gain access to the best healthcare and long-term care investment intelligence, data, and analysis.
